依达拉奉右莰醇联合氯吡格雷治疗急性脑梗死对患者炎性因子水平的影响分析王平明王兴书冯清春梁赋

往期阅览 · All Issues-> 2025年 · 2025

中外临床医学，2025年，第1卷，第2期，第109-112页，pISSN 3080-7611、eISSN 3080-762X

发布者：Quest Press

发布日期：2025/10/19

doi 10.12479/questpress-zwlcyx.20250225

Open Access

浏览457次

Download PDF | 全文下载

依达拉奉右莰醇联合氯吡格雷治疗急性脑梗死对患者炎性因子水平的影响分析

王平明,王兴书,冯清春,梁赋

海口市第三人民医院，海南海口，571100

摘要：目的探究在急性脑梗死诊疗方案中施以依达拉奉右莰醇+氯吡格雷药物联合治疗，对患者炎性因子水平的具体影响价值。方法研究择选时间控制在2024.3月至2025.3月期间，样本容量总计占70 例，均为我院收治的急性脑梗死患者，入选患者参照“摸球法”分为对照组（35 例）与观察组（35例）；对照组施以氯吡格雷用药，观察组在对照组基础上加用依达拉奉右莰醇；比较2 组患者神经缺损程度、凝血功能、炎性因子水平。结果观察组神经缺损程度分值较之对照组有所降低P＜0.05；观察组各项凝血功能指标相比对照组改善明显P ＜ 0.05；以对照组数值作为参照，观察组炎性因子水平更低P＜0.05。结论将氯吡格雷与依达拉奉右莰醇联合干预用于临床对急性脑梗死的治疗过程中，便于促进神经功能提升，改善机体凝血功能，有效抑制炎性因子水平释放，疗效显著。

关健词：依达拉奉右莰醇；氯吡格雷；急性脑梗死；炎性因子水平

Analysis of the Impact of Edaravone Dexborneol Combined with Clopidogrel on Inflammatory Factor Levels in Patients with Acute Cerebral Infarction

Pingming Wang,Xingshu Wang,Qingchun Feng,Fu Liang

Haikou Third People’s Hospital， Haikou Hainan 571100，china

Abstract: Objective Exploring the Use of Edaravone Dexborneol in the Treatment Regimen for Acute Cerebral Infarction+-clopidogrel combination therapy，The clinical significance of its effect on patients’ inflammatory factor levels。Methods Theparticipant recruitment period was set from March 2024 to March 2025，A total of 70 cases were included，All participantswere patients with acute cerebral infarction admitted to our hospital。The enrolled patients were assigned to either a controlgroup (n=35) or an observation group (n=35) by means of the random drawing method；The control group received clopidogreltherapy，The observation group received Edaravone Dexborneol in addition to the control regimen；Neurological deficit,coagulation function, and inflammatory factor levels were compared between the two groups。Results The observation groupdemonstrated a significantly lower neurological deficit score than the control group (P < 0.05)；The observation group showedsignificant improvement in all coagulation parameters compared to the control group (P < 0.05)；Data are presented relative tothe control group values，The observation group had significantly lower levels of inflammatory factors than the control group (P< 0.05)。Conclusion Clopidogrel combined with edaravone dexborneol for clinical intervention in the treatment of acute cerebralinfarction，It effectively promotes neurological function, improves the body’s coagulation mechanism, and significantlysuppresses the release of inflammatory factors, demonstrating remarkable therapeutic efficacy。

Keywords : Edaravone dexborneol; Clopidogrel; Acute cerebral infarction; Inflammatory factor levels

论文收录证明 / 文献检索报告

Document Retrieval Certificate / Proof of Publication Indexing

作者贡献声明 / 贡献确认书

Author Contribution Statement / Certificate of Authorship Contribution

同行评审报告 / 评审意见

Peer Review Report / Peer Review Comments

利益冲突

Conflict of Interest

作者声明不存在任何利益冲突。

The author declares no conflict of interest.

本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问： https://creativecommons.org/licenses/by/4.0/。

This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.